(1) Exploratory biomarker analyses from an ongoing phase 1 study of Daiichi Sankyo Company, Limited's (hereafter, Daiichi Sankyo) patritumab deruxtecan, a HER3 directed DXd antibody drug conjugate (ADC), in patients with previously treated EGFR-mutated metastatic/unresectable non-small cell lung cancer (NSCLC) were highlighted in a poster presentation today at the IASLC 2020 World Conference on Lung Cancer (WCLC), hosted by the International Association for the Study of Lung Cancer. Lung cancer is the leading cause of cancer death among both men and women, and accounts for about one-fifth of all cancer deaths globally, with 80 to 85 percent classified as NSCLC. 1,2 For patients with metastatic disease, prognosis is particularly poor, as only 6 to 10 percent live beyond five years after diagnosis.